Oncotype DX uses a tissue sample from a breast cancer tumor, typically from a core biopsy or surgery, to analyze the activity of a specific set of genes within the cancer cells.
Ended Awarded Last action
- Contract number
- HT940825FE016
- Awardee
-
Exact Sciences Corporation UEI NGBXEJX5GLE9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $69,498
Award facts
- Contract value 100% obligated
- $69,498.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Eglin AFB, FL 32542, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $69.5K delivery order to Exact Sciences Corporation for Oncotype DX breast cancer genomic testing services, with performance at Eglin Air Force Base in Florida. This firm fixed-price contract, awarded September 26, 2025, represents a task order under the company's existing blanket purchase agreement with DHA for oncology testing services. Oncotype DX analyzes gene expression within breast cancer tumor tissue samples obtained from core biopsies or surgical procedures to assess cancer-specific genetic activity and inform treatment decisions. The contract is non-set-aside and will be completed by October 27, 2025.
This delivery order is issued under Exact Sciences Laboratories, LLC's position on the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule, through which the company maintains multiple blanket purchase agreements with the Department of Veterans Affairs and Defense Health Agency valued at millions of dollars. Exact Sciences has established itself as a primary provider of specialized genomic and molecular diagnostic services to federal healthcare agencies, delivering advanced cancer screening and detection testing across military and VA medical facilities. The company's expertise in gene expression profiling and personalized medicine diagnostics positions it as a critical vendor supporting the Defense Health Agency's oncology testing requirements for military beneficiaries.
Quick answers
Who was awarded contract HT940825FE016?
HT940825FE016 was awarded to Exact Sciences Corporation by Defense Health Agency (Department of Defense) on September 26, 2025.
How much is contract HT940825FE016 worth?
The government has obligated $69,498 on HT940825FE016.
Is contract HT940825FE016 an order under another contract?
Yes. HT940825FE016 is a delivery order under V797D70053, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract HT940825FE016 competed?
The extent of competition for HT940825FE016 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award